title: Effect of glutamate receptor antagonists microinjected into the nucleus accumbens on place aversion induced by naloxone in single-dose, morphine-treated rats.
abstract: It is well established that acute morphine withdrawal can be observed following opioid receptor antagonism in rodents. Glutamate receptor antagonists can attenuate the conditioning place aversion (CPA) induced by naloxone in single-dose, morphine-treated rats. Anatomically, the nucleus accumbens appears to be involved in opiate dependence. In the present study, we examined the effects of various glutamate receptor antagonists in the nucleus accumbens on naloxone-induced CPA in rats. MK-801 (an NMDA receptor antagonist), GYKI52466 (an AMPA receptor antagonist), and MCPG (a metabotropic glutamate receptor antagonist) significantly attenuated naloxone-induced CPA following microinjection into the accumbens. In contrast, none of the agents showed place conditioning ability on their own in either morphine-exposed or naïve rats. The present study suggests that glutamate receptors in the nucleus accumbens play a key role in the motivational component of withdrawal during acute morphine dependence.
authors.affiliation: Department of Hospital Pharmacy, Okayama University Medical School, 2-5-1, Shikata-cho, Okayama 700-8558, Japan.
authors.forename: Yoichi
authors.initials: Y
authors.lastname: Kawasaki
authors.forename: Shigeru
authors.initials: S
authors.lastname: Ishida
authors.forename: Chunyu
authors.initials: C
authors.lastname: Jin
authors.forename: Yoshihisa
authors.initials: Y
authors.lastname: Kitamura
authors.forename: Hiromu
authors.initials: H
authors.lastname: Kawasaki
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Gomita
authors.forename: Toshiaki
authors.initials: T
authors.lastname: Sendo
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Araki
mesh_terms: D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects / Q000502:physiology; D018691:Excitatory Amino Acid Antagonists / Q000008:administration & dosage* / Q000494:pharmacology*; D018698:Glutamic Acid / Q000378:metabolism; D008297:Male; D008845:Microinjections; D009020:Morphine / Q000494:pharmacology*; D009021:Morphine Dependence / Q000378:metabolism / Q000503:physiopathology; D009042:Motivation / Q000187:drug effects / Q000502:physiology; D009270:Naloxone / Q000494:pharmacology*; D009714:Nucleus Accumbens / Q000187:drug effects* / Q000378:metabolism / Q000503:physiopathology; D051381:Rats; D017207:Rats, Sprague-Dawley; D017470:Receptors, Glutamate / Q000378:metabolism*; D013037:Spatial Behavior / Q000187:drug effects* / Q000502:physiology; D013375:Substance Withdrawal Syndrome / Q000378:metabolism / Q000503:physiopathology
chemical_list: D018691:Excitatory Amino Acid Antagonists; D017470:Receptors, Glutamate; D009270:Naloxone; D018698:Glutamic Acid; D009020:Morphine